Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Our commitment is to make every effort to support patients in need of treatment options.
Atara’s pipeline includes tab-cel® (tabelecleucel), which is in Phase 3 development for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disorder (EBV+ PTLD) as well as in earlier stage development for other EBV-associated hematologic malignancies and solid tumors, including nasopharyngeal carcinoma (NPC).
PTLD is a type of cancer or lymphoma that may occur after bone marrow or organ transplant. A patient who receives a transplant must take medications to suppress their immune system (immunosuppression) so that their body will not reject the new bone marrow or organ. When the immune system is suppressed, it is easier to become sick. Sometimes when a transplant patient is infected with Epstein-Barr virus (EBV), the virus may cause a serious cancer or lymphoma known as PTLD.
If you are interested in learning more about our ongoing clinical studies, please contact us at ClinicalStudies@atarabio.com.
More information about Atara’s ongoing clinical studies can be found here.
We also recognize our clinical studies may not be available to all patients who have life threatening diseases and no satisfactory treatment alternatives. Learn more about Atara’s expanded access programs and compassionate use policy here.